Site Management/Investigator Payments Featured Articles

  1. Why Site Relationships With Sponsors and CROs Must Evolve Now 11/24/2025

    Sites are central to drug development — we cannot run a trial without them — yet the industry continues to treat them as tactical, temporary instruments. It’s time to break this cycle, implores Jim Kremidas, executive director, Association of Multisite Research Corporations (AMRC).

  2. Site Payments Are Still a Mess, But Takeda Is Trying To Help 11/19/2025

    In this article, Heidi Barham, Takeda’s associate director of clinical study site payments, explains how the company is replacing opaque CRO-driven processes with real-time transparency, streamlined startup payments, and a dedicated sponsor-side team that sites can actually reach.

  3. Everyone Talks About Site Selection — But Few Actually Get It Right 11/14/2025

    The site selection process is complicated by outdated data, limited operational insight, and overreliance on reputation. Discover some practical ways to evaluate site feasibility for your next trial.

  4. Turning Site-Centric From Slogan To Reality 11/12/2025

    SCRS’s Collaborate Forward initiative aims to move “site-centricity” from industry buzzword to operational reality. By documenting how sponsors, CROs, and technology providers are improving feasibility, budgeting, contracting, and patient recruitment through measurable collaboration practices, SCRS is working to provide the industry with a playbook for better site relationships and trial execution.

  5. Heading For An M&A? Understand The Risks And Mitigation Strategies For Clinical Trial Agreements 11/10/2025

    Learn the key considerations to anticipate and mitigate risks that CTAs and diligence in the clinical trial space present during mergers and acquisitions (M&As).

  6. Sites Are 3X Likely To Die In The First Year Than New Businesses 11/7/2025

    Milken Institute Health Director of Research Andrew Friedson, Ph.D., reveals the stark truth of site survivability and discusses how factors like available population and local economic conditions factor into survival rates.

  7. Sponsors Collect Too Much "Non-Essential" Data, Say Tufts And TransCelerate 11/6/2025

    A collaboration between Tufts CSDD, Tufts School of Medicine, and TransCelereate BioPharma revealed just how much extra data sponsors are collecting — and why that's a problem.

  8. Global Implications Of Zero Tariffs On Indian Pharma Exports To China 11/5/2025

    Discover the worldwide impacts of China’s zero-tariff policy on Indian pharmaceutical drugs.

  9. Participant Recruitment In LMIC Clinical Trials 11/5/2025

    Due to the high burden of infectious diseases in low- and middle-income countries (LMICs), there is greater urgency for vaccine trials. Participant recruitment entails significant work with communities.

  10. Behavior Modeling Can Help Sponsors Better Understand Sites And Patients 11/4/2025

    Learn how behavioral modeling can identify patients at risk of dropout and sites that may need additional support, so you can build a more resilient research network.